Biomarker identification using dynamic time warping analysis: a longitudinal cohort study of patients with COVID-19 in a UK tertiary hospital
Authors
Burke, H.Freeman, A.
O'Regan, P.
Wysocki, Oskar
Freitas, Andre
Dushianthan, A.
Celinski, M.
Batchelor, J.
Phan, H.
Borca, F.
Sheard, N.
Williams, S.
Watson, A.
Fitzpatrick, Paul
Landers, Donal
Wilkinson, T.
Affiliation
Faculty of Medicine, University of Southampton, Southampton, UK. Faculty of Medicine, University of Southampton, Southampton, UK a.freeman@soton.ac.uk. Digital Experimental Cancer Medicine Team, Cancer Biomarker Centre, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, UK. Clinical Informatics Research Unit, University of Southampton Faculty of Medicine, Southampton, UK. University of Southampton, Southampton, UK. Institute for Life Sciences, University of Southampton, Southampton, UK. University Hospital Southampton NHS Foundation Trust, Southampton, UK. University of Manchester, Cancer Biomarker Centre, Cancer Research UK Manchester Institute, Manchester, UK. Digital Experimental Cancer Medicine Team, University of Manchester, Cancer Biomarker Centre, Cancer Research UK Manchester Institute, Alderley Edge, Cheshire, UK.Issue Date
2022
Metadata
Show full item recordAbstract
Objectives COVID-19 is a heterogeneous disease, and many reports have described variations in demographic, biochemical and clinical features at presentation influencing overall hospital mortality. However, there is little information regarding longitudinal changes in laboratory prognostic variables in relation to disease progression in hospitalised patients with COVID-19. Design and setting This retrospective observational report describes disease progression from symptom onset, to admission to hospital, clinical response and discharge/death among patients with COVID-19 at a tertiary centre in South East England. Participants Six hundred and fifty-one patients treated for SARS-CoV-2 between March and September 2020 were included in this analysis. Ethical approval was obtained from the HRA Specific Review Board (REC 20/HRA/2986) for waiver of informed consent. Results The majority of patients presented within 1 week of symptom onset. The lowest risk patients had low mortality (1/45, 2%), and most were discharged within 1 week after admission (30/45, 67%). The highest risk patients, as determined by the 4C mortality score predictor, had high mortality (27/29, 93%), with most dying within 1 week after admission (22/29, 76%). Consistent with previous reports, most patients presented with high levels of C reactive protein (CRP) (67% of patients >50 mg/L), D-dimer (98%>upper limit of normal (ULN)), ferritin (65%>ULN), lactate dehydrogenase (90%>ULN) and low lymphocyte counts (81%<lower limit of normal (LLN)). Increases in platelet counts and decreases in CRP, neutrophil:lymphocyte ratio (p<0.001), lactate dehydrogenase, neutrophil counts, urea and white cell counts (all p<0.01) were each associated with discharge. Conclusions Serial measurement of routine blood tests may be a useful prognostic tool for monitoring treatment response in hospitalised patients with COVID-19. Changes in other biochemical parameters often included in a ‘COVID-19 bundle’ did not show significant association with outcome, suggesting there may be limited clinical benefit of serial sampling. This may have direct clinical utility in the context of escalating healthcare costs of the pandemic.Citation
Burke H, Freeman A, O’Regan P, Wysocki O, Freitas A, Dushianthan A, et al. Biomarker identification using dynamic time warping analysis: a longitudinal cohort study of patients with COVID-19 in a UK tertiary hospital [Internet]. Vol. 12, BMJ Open. BMJ; 2022. p. e050331.Journal
BMJ OpenDOI
10.1136/bmjopen-2021-050331PubMed ID
35168965Additional Links
https://dx.doi.org/10.1136/bmjopen-2021-050331Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1136/bmjopen-2021-050331
Scopus Count
Collections
Related articles
- Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
- Authors: Dioh W, Chabane M, Tourette C, Azbekyan A, Morelot-Panzini C, Hajjar LA, Lins M, Nair GB, Whitehouse T, Mariani J, Latil M, Camelo S, Lafont R, Dilda PJ, Veillet S, Agus S
- Issue date: 2021 Jan 11
- Mortality predictors of hospitalized patients with COVID-19: Retrospective cohort study from Nur-Sultan, Kazakhstan.
- Authors: Pya Y, Bekbossynova M, Gaipov A, Lesbekov T, Kapyshev T, Kuanyshbek A, Tauekelova A, Litvinova L, Sailybayeva A, Vakhrushev I, Sarria-Santamera A
- Issue date: 2021
- Research Evaluation Alongside Clinical Treatment in COVID-19 (REACT COVID-19): an observational and biobanking study.
- Authors: Burke H, Freeman A, Dushianthan A, Celinski M, Batchelor J, Phan H, Borca F, Kipps C, Thomas GJ, Faust SN, Sheard N, Williams S, Fitzpatrick P, Landers D, Wilkinson T
- Issue date: 2021 Jan 22
- A randomized open-label trial to evaluate the efficacy and safety of triple therapy with aspirin, atorvastatin, and nicorandil in hospitalised patients with SARS Cov-2 infection: A structured summary of a study protocol for a randomized controlled trial.
- Authors: Sharma A, Sharma C, Raina S, Singh B, Dadhwal DS, Dogra V, Gupta S, Bhandari S, Sood V
- Issue date: 2021 Jul 15
- Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial.
- Authors: Garcia-Vicuña R, Abad-Santos F, González-Alvaro I, Ramos-Lima F, Sanz JS
- Issue date: 2020 Sep 9